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Overweight and obesity are usually related with high fat and calorie intake, and seriously causative of
lifestyle-related diseases such as cardiovascular disorders, arteriosclerosis, and colon cancer. In this study,
we propose a novel dietary therapy against overweight and obesity using mixtures of protamine and
chitooligosaccharide (COS), which are known to interrupt the lipid metabolism in the body. Protamine is
a dietary protein originated from salmon reproductive organ, and COS is an oligosaccharide made from
chitin or chitosan by chemical or enzymatic hydrolysis. In the enzyme activity analysis in vitro, protamine
and COS strongly suppressed the activity of pancreatic lipase, which is the primary enzyme for the
digestion and absorption of lipids in the intestine. In in vivo animal test, the mixtures of protamine and
COS significantly reduced the serum levels of triglyceride (TG), total cholesterol (T-CHO), and low density
lipoprotein-cholesterol (LDLC) and inhibited the accumulation of lipids in liver tissue of Sprague Dawley
(SD) rats fed high fat diets. On the other hand, they increased fecal TG and T-CHO contents. From these
alterations in lipid metabolism, we verified that protamine and COS mixtures could effectively interrupt
the digestion and absorption of dietary lipids in the body by inhibiting pancreatic lipase activity. In
addition, protamine and COS mixtures increased the serum level of high density lipoprotein-cholesterol
(HDLC), responsible for removing cholesterol from cells and protecting atherosclerosis, and therefore
decreased the potential risks of cardiovascular diseases by lowering values of the atherogenic index (AI)
and cardiac risk factor (CRF). Taken together, we suggest protamine and COS mixtures as a prominent
dietary therapy for the prevention of overweight, obesity, and further cardiovascular diseases related with
hyperlipidemia. 
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In the aftermath of industrialization, eating habits of
South Korea have changed to Western diets, including
bread, meat, liquor, and fast food, which sometimes can
be related with high fat and calorie intake. Recently, a
frequent ‘get-together’, one of distinctive sociocultural
events in South Korea, also causes overweight by
excessive drinking and meat-eating. For these reasons,
the number of overweighed and obese people has been
increasing in the last few decades. The World Health
Organization (WHO) claims that 45% of Korean men
and 54% of women are overweighed in 2005, and the
percentages are expected to increase to 66% and 67%,
respectively by 2015. The overweight and obesity are
often involved with cardiovascular disorders, arteriosclerosis,
colon cancer, and other diseases [1]. Some studies have
shown that dietary therapy is important and could be
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considered as the first choice in the treatment of
disorders resulting from overweight and obesity [2]. In
the present study, we propose the dietary mixtures of
protamine and chitooligosaccharide (COS) with the
prominent improvement effect on lipid metabolism as a
novel strategy against overweight due to high fat ingestion.
Protamine is a protein originated from salmon sperm.
It has a low molecular weight of around 4,000-5,000 and
functions in protecting DNA damage and restricting fat
absorption in the intestine [3]. In addition, protamine is
widely used as a natural food preservative due to strong
antibacterial effect [4]. In terms of lipid metabolism,
protamine has been proved to be effective in reducing
weight gain and body fat accumulation through the
inhibition of dietary fat absorption, because it strongly
inhibits the hydrolysis of triglycerides, which is a
process needed for absorption of lipid into the intestine
[5]. Another candidate for dietary therapy, COS, is an
oligosaccharide made from chitin or chitosan by chemical
or enzymatic hydrolysis. Polysaccharides, chitin or
chitosan, have limited application as nutrient source due
to their insolubility and high viscosity. On the other
hand, as COS has low molecular weight, good solubility,
and low viscosity [6,7], it can be diversely used in many
formulations. Several recent studies have identified
various health benefits of COS. For example, COS has
shown to have anti-bacterial and anti-fungal activities
and to enhance immune function [8,9]. In addition, it
restores healthy blood pressure, reduces cholesterol, and
prevents alcoholic liver disease [10]. Especially, COS
has also been shown to reduce the triglyceride level in
obese diabetic mice [11,12]. and COS was evaluated as
an effective dietary supplement for lowering cholesterol
level in healthy men [13]. Therefore, COS has recently
attracted highly attention as a new biomedical.
This study was conducted to examine the possibility of
the protamine and COS mixtures as a dietary therapy
against overweight and obesity focusing on lipid metabolism.
We evaluated whether these mixtures suppress the
pancreatic lipase activity in vitro and further restraint the
lipid metabolism and absorption in vivo. Male Sprague
Dawley (SD) rats were used in the in vivo animal test
and the contents of TG, T-CHO, HDLC, and LDLC in
serum or feces were measured after the dietary
administration of the protamine and COS mixtures with
high fat diet to rats. Also, the lipid accumulation in liver




Salmon protamine (hydrochloride salt, Maruha Nichiro
Foods, Japan) and COS (CNA Biotech, Cheongwon,
Republic of Korea) were provided by LG Household &
Health Care Research (Deajeon, Republic of Korea).
Protamine and COS have a purity of 98% and 88%,
respectively. All other chemicals used were of reagent
grade.
Pancreatic lipase activity assay
The pancreatic lipase activity was measured using 4-
methylumbelliferyl oleate (4-MU oleate) as a substrate.
The samples of protamine or COS were prepared at
various concentrations dissolved in distilled water. The
concentrations of protamine samples were 0, 2, 4, 8, 16,
32, 64, and 100 µg/mL, and the concentrations of COS
samples were 0, 5, 25, 50, 75, 100, 200, and 300 µg/mL.
Firstly, 5 µL of each sample was put in 96-wells plate
and then added with 50 µL of 0.1 mM 4-MU solution
buffer (13 mM Tris-HCl, 150 mM NaCl, and 1.3 mM
CaCl2, pH8.0). Twenty five µL of the porcine pancreatic
lipase solution dissolved in the above buffer (50 U/mL)
was then added to start the enzyme reaction. After
incubation at 36
oC for 30 min, 0.1 mL of 0.1 M sodium
citrate (pH 4.2) was added to stop the reaction [14,15].
The amount of 4-methylumbelliferone released by lipase
was measured at 450 nm using an ELISA-Reader
(VERSA man, Molecular Devices, Sunnyvale, CA,
USA).
Animal care
Healthy male SD-rats were purchased from Central
Lab Animal, Inc. (Seoul, Republic of Korea). Seven-
week-old male SD-rats were housed in a conventional-
facility at the Laboratory Animal Research Center of
Chungbuk National University (Cheongju, Republic of
Korea). The animals were maintained in a room with
constant temperature of 22±
oC, relative humidity of
55±10%, and 12 h light/dark cycle, and fed standard
rodent chow. Rats were allowed to acclimate for 1 week
after arrival. All animals were used for the in vivo
experiments in accordance with the approved institutional
guidelines of Chungbuk National University. The
experiment was allowed to conduct by Institution
Animal Care IACUC and use committee of Chungbuk
National University (CBNUA-363-11-01).Inhibitory effects of protamine and chitooligosaccharide on high-fat diet fed SD-rats 33
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Experimental diets preparation
A high-fat diet was prepared as corn oil suspension by
mixing the 6 mL of corn oil (Sigma-Aldrich, St. Louis,
MO, USA), 80 mg of cholic acid (Sigma-Aldrich), 2 mg
of cholesteryl oleate (Sigma-Aldrich), and 1 mg of
margarine (Seoul Milk Ltd., Seoul, Republic of Korea)
in 6 mL of distilled water [16]. The mixture diets of
protamine and COS were made by adding protamine and
COS at various ratios into the above corn oil suspension.
The PO2.1 mixture contained protamine 2.1 mg/kg body
weight (b.w.) and COS 25 mg/kg b.w. in corn oil
suspension (protamine:COS=1:12), PO4.2 mixture
protamine 4.2 mg/kg b.w. and COS 25 mg/kg b.w.
(protamine:COS=1:6), and PO8.3 mixture protamine
8.3 mg/kg b.w. and COS 25 mg/kg b.w. (protamine:
COS=1:3).
Administration of experimental diets to rats
Male SD-rats, weighing 296.86±2.46 g, were divided
into four groups and 3 mL of experimental diet was
administered once to each rat via a Zonde needle. The
vehicle group (n=6) was treated only with corn oil
suspension. Other experimental groups (each group, n=
5) were administered with the mixture diets of protamine
and COS added in corn oil suspension. Before the oral
administration of experimental diets, all rats were
starved except water for 18 h and then blood samples
were collected from the tail vein (0 h). After the
administration, blood samples were collected at 3, 9, and
24 h. The feces were also collected from each group at
0, 3, 9, and 24 h and stored at −20
oC until analysis.
Analysis of serum and fecal lipids
Blood samples (0.5~0.7 mL) were left at room
temperature for 1 h, and then serum was prepared by
centrifugation at 4
oC, 3,000 rpm for 20 min and then
stored at −20
oC. Serum analysis was conducted by
HITACHI Clinical Analyzer 7080 (Hitachi Korea Ltd.,
Seoul, Korea) to measure the serum concentrations of
various lipids including TG, T-CHO, HDLC, and LDLC.
The AI and CRF were converted from serum HDLC and
T-CHO concentrations. The AI was calculated as (T-
CHO-HDLC) / HDLC. The CRF was calculated as (T-
CHO/HDLC). Next, the collected feces were analyzed for
fecal lipids. The fecal crude fat was extracted by Rose-
Gottlieb method [17]. Five g of the feces was put into
Mojonnier fat-extractor, added with 6 mL NH4OH (OCI
Company Ltd., Ulsan, Republic of Korea), and then left
for 3 min. This mixture was mixed with 12 mL of 95%
alcohol (OCI Company Ltd.), 25 mL of ether (OCI
Company Ltd.), and 25 mL of petroleum ether (OCI
Company Ltd.), and then left at room temperature for
1~2 h. Finally, fecal crude fat was collected by
withdrawing the supernatant consisted of ether phase at
75
oC and analyzed for TG and T-CHO. Fecal TG was
measured by triglyceride assay kit (Cayman Chemical
Company,  Ann Arbor, MI, USA) according to the
manufacturer’s method. Fecal T-CHO was analyzed by
Enzychrome cholesterol assay kit (BioAssay Systems,
Hayward,  CA, USA) according to the manufacturer’s
method.
Histological analysis by Oil-red-O staining
After 24 h of oral administration with experimental
diets, the liver tissues were harvested from the sacrificed
rats and then immediately frozen up in − 80
oC deep
freezer. Frozen liver tissues were cryo-sectioned 6-µm
thick, fixed in 10% formalin solution (OCI Company
Ltd.) at 4
oC for 5 min, and then rinsed 3 times with
distilled water. 5% Oil-red-O working solution was
prepared by dissolving Oil-red-O powder (Sigma-Aldrich)
in Propylene Glycol (OCI Company Ltd.) and used to
stain the sectioned tissues according to the standard
methods of manufacturer’s. Counter staining was
conducted with the hematoxylin (Sigma-Aldrich) and
then mounted with glycerin (OCI Company Ltd.). The
lipid containing cells were detected as the red spot using
a light microscope (BX51 U-LH100HGWIG, Olympus,
Tokyo, Japan; ×40, ×200, and ×400 magnification).
Statistical analysis
All data were analyzed with GraphPad Prism software
(San Diego, CA, USA) [18,19]. The in vitro data are
presented as the mean±SD and in vivo data as the
mean±SEM. Statistical analysis was performed using a
one-way ANOVA followed by Dunnett’s multiple
comparison test. P-values <0.05 were considered to be
statistically significant.
Results
Pancreatic lipase activity in vitro
Protamine and COS significantly inhibited pancreatic
lipase activity in vitro. The enzyme activity was decreased
by 29% at 2 µg/mL of protamine, and by 93% at 32 µg/
mL of protamine, respectively (Figure 1A). The COS34 Nam-Hee Kang et al.
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also considerably inhibited pancreatic lipase activity,
which was suppressed by 87% at 5 µg/mL of COS as
shown in Figure 1B.
Serum lipids concentrations
The contents of various types of lipid in serum
including TG, T-CHO, HDLC, and LDLC were analyzed
from the rats administered with experimental diets. The
serum TG concentrations in vehicle group rapidly
increased after the intake of high fat diet. But, PO2.1,
PO4.2, and PO8.3 groups significantly inhibited the
serum TG concentrations by 51, 54, and 47%, respectively,
at 3 h, and 37, 56, and 57%, respectively, at 9 h
compared with vehicle group (Figure 2A). Serum T-
CHO concentration also effectively decreased by protamine
and COS mixtures. PO2.1, PO4.2, and PO8.3 groups
significantly decreased serum T-CHO by 30, 36, and
22%, respectively, at 3 h, and 34, 36, and 21%,
respectively, at 9 h compared with vehicle group as seen
in Figure 2B. Serum HDLC concentrations of PO 2.1,
Figure 1. Pancreatic lipase activity. (A) The pancreatic lipase activity was inhibited by protamine. Protamine was used at the
concentrations of 0, 2, 4, 8, 16, 32, 64, and 100 µg/mL. (B) The pancreatic lipase activity was inhibited by chitooligosaccharide
(COS).The COS was used at the concentrations of 0, 5, 25, 50, 75, 100, 150, and 300 µg/mL. Values represent the mean±SD.
*P<0.05 (Dunnett’s multiple comparison test). 
Figure 2. Serum lipid analysis. (A) Triglyceride in serum was measured after the oral administration of various mixtures of
protamine and chitooligosaccharide (COS) in corn oil suspension. (B) Total-cholesterol in serum (C) High density lipoprotein-
cholesterol (HDLC) (D) Low density lipoprotein-cholesterol (LDLC).The ratios of protamine and COS in the mixtures were 1:3, 1:6,
and 1:12. The PO2.1 group was treated with 2.1 mg/kg body weight (b.w.) of protamine and 25 mg/kg b.w. of COS in corn oil
suspension. The PO4.2 group was treated with 4.2 mg/kg b.w. of protamine and 25 mg/kg b.w. of COS in corn oil suspension. The
PO8.3 group was treated with 8.3 mg/kg b.w of protamine and 25 mg/kg b.w of COS in corn oil suspension. Values represent the
mean±SEM. *P<0.05 (Dunnett’s multiple comparison test). Inhibitory effects of protamine and chitooligosaccharide on high-fat diet fed SD-rats 35
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PO 4.2, and PO 8.3 groups were increased by 24, 39, and
33%, compared with vehicle group at 24 h (Figure 2C).
Serum LDLC concentrations of PO 2.1, PO 4.2, and PO
8.3 groups were decreased by 39, 40, and 32%,
respectively, compared with vehicle group at 24 h as
shown in Figure 2D.
Atherogenic index and cardiac risk factor
The AI and CRF of rats fed protamine and COS
mixtures were significantly decreased compared with
vehicle group as demonstrated in Table 1. The CRF of
PO 4.2 group was decreased by 76% and AI of PO 2.1
group was decreased by 45%.
Fecal triglyceride and cholesterol concentrations
Protamine and COS mixture diets significantly increased
the TG and T-CHO contents in feces compared to high
fat diet administered to vehicle group. The fecal TG
concentration of PO 2.1 group was highly increased by
lapse of time up to 91% at 24 h (Figure 3A). The fecal
T-CHO concentration of PO 4.2 group was increased up
to 68% at 3 h. The PO 2.1 group gradually increased the
fecal T-CHO and the PO 8.3 group effectively increased
the fecal T-CHO only at 9 h as seen in Figure 3B.
Lipid accumulation in liver tissue
The lipids accumulated in rat liver tissues obtained
from each experimental group were detected as red spots
in the histological analysis by Oil-red-O staining. The
red spots show the lipid components which were
digested from TG and T-CHO in high-fat diet by
pancreatic lipase, absorbed into the intestine, and then
accumulated in the liver. The red spot areas stained with
lipids were observed in vehicle group, but not in
protamine and COS mixture groups as demonstrated
Figure 4.
Discussion
Protamine from salmon reproductive organ is a dietary
protein rich in the basic amino acid arginine and is
known to be effective in reducing fat accumulation in the
body through the inhibition of lipid absorption like other
dietary proteins including soy and fish proteins [20,21].
COS is an oligosaccharide obtained from polysaccharides,
chitin or chitosan, by chemical or enzymatic hydrolysis
and has been recently evaluated as an effective dietary
supplement for lowering cholesterol level in healthy men
and animals [11,13]. In this study, we provide the
Figure 3. Fecal lipid analysis. (A) Triglyceride concentration in feces. (B) Total-cholesterol concentration in feces. The PO2.1 group
was treated with 2.1 mg/kg body weight (b.w.) of protamine and 25 mg/kg b.w. of COS in corn oil suspension. The PO4.2 group
was treated with 4.2 mg/kg b.w. of protamine and 25 mg/kg b.w. of COS in corn oil suspension. The PO8.3 group was treated with
8.3 mg/kg b.w. of protamine and 25 mg/kg b.w. of COS in corn oil suspension. Values represent the mean±SEM. *P<0.05
(Dunnett’s multiple comparison test).
Table 1. Contents of CRF and AI in serum of SD-rats fed a high-fat diet containing various mixtures of protamine and
chitooligosaccharide
Group Vehicle







1)Vehicle: high-fat diet, PO2.1: high-fat diet+protamine 2.1 mg/kg body weight (b.w.)+chitooligosaccharide (COS) 25 mg/kg b.w., PO4.2:
high-fat diet+protamine 4.2 mg/kg b.w.+COS 25 mg/kg b.w., PO8.3: high-fat diet+protamine 8.3 mg/kg b.w.+COS 25 mg/kg b.w.
2)CRF (cardiac risk index): total cholesterol (T-CHO)/ high density lipoprotein cholesterol (HDLC)
3)AI (artherogenic index): (T-CHO-HDLC)/HDLC
4)The results are mean±SEM of 3 rats per each group. *P<0.05 (Dunnett’s multiple comparison test).36 Nam-Hee Kang et al.
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mixtures of protamine and COS, two prominent candidates
related with lipid metabolism, as a novel dietary therapy
for overweight and obesity. We evaluated the inhibitory
effect on lipid metabolism of these mixtures in vivo
through the analysis on the serum and fecal lipid
contents and lipid accumulation in liver tissues within
Figure 4. Histological analysis on liver tissues. (A) The liver tissue of vehicle group. (B) The PO2.1 group. (C) The PO4.2 group. (D)
The PO8.3 group. After 24 h of oral ministration of protamine and COS mixtures, we harvested the liver tissues from rats. Frozen
liver tissues were cryo-sectioned, cut 6-ìm thick, and stained with the 5% Oil-red-O working solution by standard methods of
manufacturer’s. Counter staining was conducted with the hematoxylin and then mounted with glycerin. The lipid containing cells
are shown the red spots under a light microscope (BX51 U-LH100HGWIG, Olympus; ×40, ×200, and ×400 magnification).Inhibitory effects of protamine and chitooligosaccharide on high-fat diet fed SD-rats 37
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24 h after the administration of high fat diets to SD rats.
The mixture of protamine and COS significantly
decreased the serum TG concentration, which was
rapidly increased in a short time (3 h) after the intake of
high fat diets. The serum TG concentration was decreased
by about 50% by these mixtures at 3 h. For serum
cholesterols, T-CHO and LDLC concentrations were
also increased by high fat diets, while protamine and
COS mixtures effectively decreased their levels at 3 h.
On the other hand, HDLC was increased by these
mixtures within 24 h compared with high fat diets.
Unlike the serum level, the TG concentration in the feces
was considerably increased by these mixtures in the
same period time. The T-CHO concentration in feces
also showed the tendency to increase. These contrary
changes in lipid contents in serum and feces can be
explained by the lipid metabolism altered by protamine
and COS. Protamine and COS strongly suppressed the
enzyme activity of pancreatic lipase at the very low
concentration by the enzyme activity analysis. Pancreatic
lipase is the primary lipase secreted from the pancreas,
that hydrolyzes dietary lipids in the digestive system,
converting TG substrates found in ingested oils to
monoglycerides and free fatty acids. In the intestine,
monoglycerides and free fatty acids are subsequently
moved to enterocytes, cells lining the intestines and then
absorbed. Therefore, pancreatic lipase is an important
enzyme for lipid absorption in the intestine [22,23].
By strongly inhibiting the pancreatic lipase activity,
protamine and COS can effectively restrain the lipid
absorption in the intestine and induce the excretion of
lipid outside the body. The inhibitory effect on
pancreatic lipase by COS was first demonstrated in the
present study.
The apparent evidence for the hindered lipid accumulation
in the body by protamine and COS mixtures was
presented in the histological analysis, in which the liver
tissues obtained from rats fed high fat diets showed a
great deal of red spots stained with Oil-red-O working
solution, but not much spots were found in rats
administered with protamine and COS mixtures. In
addition to stimulating the excretion of dietary lipids,
protamine and COS showed to improve the cholesterol
status in the body. They decreased the serum T-CHO and
increased the fecal T-CHO, and increased the HDLC and
decreased the LDLC in serum. According to the lipid
hypothesis, abnormal cholesterol levels are strongly
associated with cardiovascular diseases because they
promote atheroma development in arteries (atherosclerosis),
which is more accurately caused by the condition of
higher concentrations of LDLC and lower concentrations
of functional HDLC [24,25].  It’s because  that LDLC
particles have been linked to atheroma formation, and on
the other hand, HDLC can remove cholesterol from cells
and atheroma and offer protection to the disease. So,
LDLC is sometimes referred to as “bad cholesterol” and
HDLC “good cholesterol”. As a result, protamine and
COS mixtures decreased the potential risks of
cardiovascular diseases by lowering values of the AI and
CRF, which are represented in terms of T-CHO and
HDLC levels in serum. A future study is required to
elucidate the mechanisms underlying the improvement
effect on cholesterol levels by protamine and COS.
In conclusion, the mixtures of protamine and COS
effectively reduced the serum TG, T-CHO, and LDLC
levels rapidly increased by high fat diets, and enhanced
the serum HDLC level. In addition, these mixtures
promoted the excretion of dietary lipids by blocking
digestion, absorption, and accumulation in the body
through their inhibition effect on the pancreatic lipase.
With these alterations in lipid metabolism, we suggest
the mixtures of protamine and COS as a prominent
dietary therapy for the prevention of overweight, obesity,
and further cardiovascular diseases related with
hyperlipidemia.
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